Hyaluronic Acid-Based Biocompatible Supramolecular Assembly for Sustained Release of Antiretroviral Drug

Byeongwoon Song, István Puskás, Lajos Szente, James Hildreth

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Human immunodeficiency virus (HIV) infection and its associated diseases continue to increase despite the progress in our understanding of HIV biology and the availability of a number of antiretroviral drugs. Adherence is a significant factor in the success of HIV therapy and current HIV treatment regimens require a combination of antiviral drugs to be taken at least daily for the remainder of a patient's life. A drug delivery system that allows sustained drug delivery could reduce the medical burden and costs associated with medication nonadherence. Here, we describe a novel supramolecular assembly or matrix that contains an anionic polymer hyaluronic acid, cationic polymer poly-L-lysine, and anionic oligosaccharide sulfobutylether-beta-cyclodextrin. HIV reverse transcriptase inhibitors Zidovudine and Lamivudine were successfully encapsulated into the polymer assembly in a noncovalent manner. The physicochemical properties and antiviral activity of the polymer assemblies were studied. The results of this study suggest that the supramolecular assemblies loaded with HIV drugs exert potent antiviral activity and allow sustained drug release. A novel drug delivery formulation such as the one described here could facilitate our efforts to reduce the morbidity and mortality associated with HIV infections and could be utilized in the design of therapeutic approaches for other diseases.

Original languageEnglish (US)
Pages (from-to)2760-2769
Number of pages10
JournalJournal of Pharmaceutical Sciences
Volume105
Issue number9
DOIs
StatePublished - Sep 1 2016

Fingerprint

Hyaluronic Acid
HIV
Polymers
Antiviral Agents
Virus Diseases
Pharmaceutical Preparations
HIV Reverse Transcriptase
Drug Compounding
Reverse Transcriptase Inhibitors
Lamivudine
Medication Adherence
Zidovudine
Drug Delivery Systems
Oligosaccharides
Lysine
Drug Liberation
Therapeutics
Morbidity
Costs and Cost Analysis
Mortality

Keywords

  • biodegradable polymers
  • controlled release
  • cyclodextrins
  • HIV/AIDS
  • macromolecular drug delivery
  • polymeric drug delivery systems

ASJC Scopus subject areas

  • Medicine(all)
  • Pharmaceutical Science

Cite this

Hyaluronic Acid-Based Biocompatible Supramolecular Assembly for Sustained Release of Antiretroviral Drug. / Song, Byeongwoon; Puskás, István; Szente, Lajos; Hildreth, James.

In: Journal of Pharmaceutical Sciences, Vol. 105, No. 9, 01.09.2016, p. 2760-2769.

Research output: Contribution to journalArticle

@article{5e946ace52d148f19337af8c36a2e95b,
title = "Hyaluronic Acid-Based Biocompatible Supramolecular Assembly for Sustained Release of Antiretroviral Drug",
abstract = "Human immunodeficiency virus (HIV) infection and its associated diseases continue to increase despite the progress in our understanding of HIV biology and the availability of a number of antiretroviral drugs. Adherence is a significant factor in the success of HIV therapy and current HIV treatment regimens require a combination of antiviral drugs to be taken at least daily for the remainder of a patient's life. A drug delivery system that allows sustained drug delivery could reduce the medical burden and costs associated with medication nonadherence. Here, we describe a novel supramolecular assembly or matrix that contains an anionic polymer hyaluronic acid, cationic polymer poly-L-lysine, and anionic oligosaccharide sulfobutylether-beta-cyclodextrin. HIV reverse transcriptase inhibitors Zidovudine and Lamivudine were successfully encapsulated into the polymer assembly in a noncovalent manner. The physicochemical properties and antiviral activity of the polymer assemblies were studied. The results of this study suggest that the supramolecular assemblies loaded with HIV drugs exert potent antiviral activity and allow sustained drug release. A novel drug delivery formulation such as the one described here could facilitate our efforts to reduce the morbidity and mortality associated with HIV infections and could be utilized in the design of therapeutic approaches for other diseases.",
keywords = "biodegradable polymers, controlled release, cyclodextrins, HIV/AIDS, macromolecular drug delivery, polymeric drug delivery systems",
author = "Byeongwoon Song and Istv{\'a}n Pusk{\'a}s and Lajos Szente and James Hildreth",
year = "2016",
month = "9",
day = "1",
doi = "10.1016/j.xphs.2016.01.023",
language = "English (US)",
volume = "105",
pages = "2760--2769",
journal = "Journal of Pharmaceutical Sciences",
issn = "0022-3549",
publisher = "John Wiley and Sons Inc.",
number = "9",

}

TY - JOUR

T1 - Hyaluronic Acid-Based Biocompatible Supramolecular Assembly for Sustained Release of Antiretroviral Drug

AU - Song, Byeongwoon

AU - Puskás, István

AU - Szente, Lajos

AU - Hildreth, James

PY - 2016/9/1

Y1 - 2016/9/1

N2 - Human immunodeficiency virus (HIV) infection and its associated diseases continue to increase despite the progress in our understanding of HIV biology and the availability of a number of antiretroviral drugs. Adherence is a significant factor in the success of HIV therapy and current HIV treatment regimens require a combination of antiviral drugs to be taken at least daily for the remainder of a patient's life. A drug delivery system that allows sustained drug delivery could reduce the medical burden and costs associated with medication nonadherence. Here, we describe a novel supramolecular assembly or matrix that contains an anionic polymer hyaluronic acid, cationic polymer poly-L-lysine, and anionic oligosaccharide sulfobutylether-beta-cyclodextrin. HIV reverse transcriptase inhibitors Zidovudine and Lamivudine were successfully encapsulated into the polymer assembly in a noncovalent manner. The physicochemical properties and antiviral activity of the polymer assemblies were studied. The results of this study suggest that the supramolecular assemblies loaded with HIV drugs exert potent antiviral activity and allow sustained drug release. A novel drug delivery formulation such as the one described here could facilitate our efforts to reduce the morbidity and mortality associated with HIV infections and could be utilized in the design of therapeutic approaches for other diseases.

AB - Human immunodeficiency virus (HIV) infection and its associated diseases continue to increase despite the progress in our understanding of HIV biology and the availability of a number of antiretroviral drugs. Adherence is a significant factor in the success of HIV therapy and current HIV treatment regimens require a combination of antiviral drugs to be taken at least daily for the remainder of a patient's life. A drug delivery system that allows sustained drug delivery could reduce the medical burden and costs associated with medication nonadherence. Here, we describe a novel supramolecular assembly or matrix that contains an anionic polymer hyaluronic acid, cationic polymer poly-L-lysine, and anionic oligosaccharide sulfobutylether-beta-cyclodextrin. HIV reverse transcriptase inhibitors Zidovudine and Lamivudine were successfully encapsulated into the polymer assembly in a noncovalent manner. The physicochemical properties and antiviral activity of the polymer assemblies were studied. The results of this study suggest that the supramolecular assemblies loaded with HIV drugs exert potent antiviral activity and allow sustained drug release. A novel drug delivery formulation such as the one described here could facilitate our efforts to reduce the morbidity and mortality associated with HIV infections and could be utilized in the design of therapeutic approaches for other diseases.

KW - biodegradable polymers

KW - controlled release

KW - cyclodextrins

KW - HIV/AIDS

KW - macromolecular drug delivery

KW - polymeric drug delivery systems

UR - http://www.scopus.com/inward/record.url?scp=84980555270&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84980555270&partnerID=8YFLogxK

U2 - 10.1016/j.xphs.2016.01.023

DO - 10.1016/j.xphs.2016.01.023

M3 - Article

C2 - 26975245

AN - SCOPUS:84980555270

VL - 105

SP - 2760

EP - 2769

JO - Journal of Pharmaceutical Sciences

JF - Journal of Pharmaceutical Sciences

SN - 0022-3549

IS - 9

ER -